Researchers found that a four-week increase in waiting times was associated with a 14 percent decrease in overall survival as well as disease-free survival. The study also indicates there still may be some benefit to chemotherapy between 12 weeks and around 4-5 months after surgery.
The analysis found no significant lack of uniformity among the studies, and results remained significant after adjustment for potential publication bias and when the analysis was repeated to exclude studies with the largest weight.
Read the JAMA study on colorectal cancer.
Related Articles on Colorectal Cancer:
Study Finds Potential for Drug-Target in Colorectal Cancer
FDA Approves FUSILEV for Colorectal Cancer Patients
Missouri Surgeon Utilizes Novel Minimally Invasive Treatment for Colorectal Cancer
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
